CYR61: A new measure of lung cancer outcome
CYR61: A new measure of lung cancer outcome
复制标题
DOI：
10.1080/02770900701512597
复制
发表时间：
2007-12-01
影响因子：
2.4
通讯作者：
Koeffler, H. Phillip
中科院分区：
文献类型：
--
作者：
Mori, Akio;Desmond, Julian C.;Koeffler, H. Phillip
富含半胱氨酸蛋白61（Cyr 61）是生长因子诱导的即刻早期基因家族的成员。本文检测了94例人肺肿瘤及其配对正常肺组织中Cyr 61 mRNA的表达。通过真实的时间逆转录-聚合酶链反应定量Cyr 61 mRNA水平，并计算为每种情况下的肿瘤/正常Cyr 61 mRNA比率。与正常匹配的肺组织相比，Cyr 61在94例肺肿瘤中的74例（79%）中表达降低。Cyr 61高表达组和低表达组之间患者特征的分布差异，如性别、年龄、肿瘤大小和病理诊断，无统计学显著性。然而，高或低Cyr 61表达组之间的临床分期分布差异具有统计学显著性;也就是说，Cyr 61低表达组在临床上比Cyr 61高表达组更晚期（p= 0.046）。此外，NO和N1疾病患者的Cyr 61水平显著高于N2患者的表达（p= 0.047）。Cyr 61极低肿瘤表达组与匹配的正常肺（39例患者）和高Cyr 61表达组（52例患者）之间的3年生存率具有统计学意义（59%对91%; p = 0.05）。综上所述，Cyr 61似乎可以预防转移性疾病，因为低表达与更晚期的疾病相关;因此，Cyr 61的表达水平与肺癌的预后相关。
Cysteine-rich protein 61 (Cyr61) is a member of a family of growth factor-inducible, immediate-early genes. In this report, the authors measured the expression of Cyr61 mRNA in 94 human lung tumors and their normal matched lung samples. The Cyr61 mRNA levels were quantified by real time reverse transcriptase-polymerase chain reaction and calculated as a tumor/normal Cyr61 mRNA ratio in each case. Compared with normal matched lung tissues, expression of Cyr61 was decreased in 74 of 94 (79 percent) lung tumors. Differences in distribution of patient characteristics, such as gender, age, tumor size, and pathological diagnosis, between high or low Cyr61 expressing groups were not statistically significant. However, differences in distribution of clinical stage between high or low Cyr61 expressing groups was statistically significant; that is, the Cyr61 low expressor group was clinically more advanced than the Cyr61 high expressor group (p= 0.046). Furthermore, Cyr61 levels of the patients with NO and N1 diseases were significantly higher than the expression in the N2 patients (p= 0.047). The 3-year survival between the Cyr61 very low tumor expressor group compared to matched normal lung (39 patients) and the higher Cyr61 expressor group (52 patients) was statistically significant (59 versus 91 percent; p = 0.05). Taken together, Cyr61 appears to guard against metastatic disease because low expression is associated with more advanced disease; and therefore, expression levels of Cyr61 correlate with the prognosis of lung cancer.